Objective: To assess the impact of therapeutic amenorrhoea triggered by triptorelin in the digestive complaints of women with deep endometriosis infiltrating the rectum.
Design: Prospective series of consecutive patients with deep endometriosis of the rectum enrolled over a period of 17 consecutive months.
Setting: University tertiary referral center.
Patients: Seventy patients.
Interventions: Medical therapy (triptorelin 11.25 mg and add-back therapy using estradiol) administered for 3.4±1.8months before surgery.
Main outcome measures: Gastrointestinal standardised questionnaires before beginning medical treatment and the day before surgery.
Results: The most frequent digestive complaints at baseline were: defecation pain in 77.1% of patients, bloating in 60%, diarrhoea in 54.3% and constipation in 50%. The largest diameter of the rectal area infiltrated by the disease was <1cm in 12.2% of women, 1 to 2.9 cm in 34.3% and ≥3cm in 51.4%. Multiple colorectal nodules were found in 32.9%. Medical treatment led to disappearance of cyclic defecation pain in 78.6%, dyschesia in 58.3%, diarrhoea in 58.3% and bloating in 50%. Relieving digestive complaints was not significantly related to either length of triptorelin administration or size of rectal infiltration by deep endometriosis.
Conclusion: Therapeutic amenorrhoea averaging 3 months allowed complete improvement of various cyclic digestive complaints in more than half of patients. In selected patients, continuous therapeutic amenorrhoea could compensate for the lack of complete resection of deep infiltrating endometriosis of the rectum, when this latter is likely to result in a high rate of postoperative morbidity.
Keywords: Agonistes de la gonadotropin releasing hormone; Aménorrhée; Colorectal endometriosis; Deep endometriosis; Endométriose colorectale; Endométriose profonde; Gonadotropin releasing hormone analogues; Medical treatment; Traitement médical; Triptorelin; Triptoréline.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.